Skip to main content
Fig. 4 | Infectious Agents and Cancer

Fig. 4

From: CRISPR/Cas9-mediated LMP1 knockout inhibits Epstein-Barr virus infection and nasopharyngeal carcinoma cell growth

Fig. 4

Regulation by the CRISPR/Cas9-mediated knockout of LMP1 or LMP2A on the proliferation of EBV in CNE-2 cells. a: Real-time quantitative PCR analysis (a) and western blotting (b) of LMP1 and LMP2A in the ‘LMP1 up’ CNE-2 cells, which were transfected with LMP1- or LMP2A-specific gRNA-Cas9 co-expression plasmids for 48 (for mRNA quantification) or 72 (for western blotting) hours; c and d: Relative EBV growth in the ‘LMP1 up’ CNE-2 cells, post the CRISPR/Cas9-mediated knockout of LMP1 or LMP2A, with a multiplicity of infection (MOI) of 0.01 for 0, 3, 6, or 12 days; virus growth was determined via the quantification of viral DNA levels of EBNA1 (c) and OriP (d). Each value was an average for triple independent results. Statistical significance was showed as * p < 0.05, ** p < 0.01, **** p < 0.0001, ns: no significance

Back to article page